

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A cyotherapeutic unit suitable for treatment of a patient in need of hematopoietic cells comprising at least ~~about one hundred~~ 1% CD34⁺ cells within a plurality of potent cells, the unit comprising cells from a plurality of sources, wherein said plurality of potent cells comprises isolated CD34⁻, OCT-4⁺ and SSEA3⁻ cells ~~that have been isolated from postpartum placenta perfusate.~~

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Previously presented) The cyotherapeutic unit of claim 1 wherein said unit comprises potent cells obtained from fetal cord blood or fetal tissue.

6. (Previously presented) The cyotherapeutic unit of claim 1 wherein said unit comprises potent cells obtained from fetal cord blood.

7.-11. (Canceled)

12. (Previously presented) The cyotherapeutic unit of claim 1 wherein said potent cells are obtained from at least two individuals.

13. (Previously presented) The cyotherapeutic unit of claim 1 wherein said potent cells are obtained from at least five individuals.

14. (Canceled)

15. (Original) The cyotherapeutic unit of claim 1 wherein at least one type of cell is excluded from the unit.

16. (Original) The cyotherapeutic unit of claim 1 wherein the plurality of potent cells is selected to render the cyotherapeutic unit suitable for therapy for an indicated disease state or condition.

17. (Original) The cyotherapeutic unit of claim 16 wherein at least one type of cell is excluded from the unit.

18. (Currently amended) A cyotherapeutic unit suitable for the treatment of a patient in need of hematopoietic cells comprising at least two preselected types of potent cells, said unit

comprising cells from a plurality of sources, wherein said potent cells comprise isolated CD34⁻, OCT-4⁺ and SSEA3⁻ cells ~~that have been isolated from postpartum placenta perfusate~~, and wherein at least ~~about one hundred~~ 1% of said potent cells are CD34⁺.

19. (Canceled)

20. (Previously presented) The cyotherapeutic unit of claim 18, distributed with a certification of the contents of said cyotherapeutic unit.

21. (Previously presented) The cyotherapeutic unit of claim 20 wherein said certification comprises an indication of cells excluded from said cyotherapeutic unit.

22. (Previously presented) The cyotherapeutic unit of claim 20 wherein said certification comprises an indication of cells absent from said cyotherapeutic unit.

23. (Previously presented) The cyotherapeutic unit of claim 20, wherein said certification indicates how the presence, absence, and/or exclusion of certain cell types render or renders the cyotherapeutic unit suitable for therapy for an indicated disease state or condition.

24.-30.(Canceled)

31. (Currently amended) A cyotherapeutic unit suitable for treatment of a patient in need of hematopoietic cells comprising (a) cells obtained from umbilical cord blood and (b) isolated CD34⁻, OCT-4⁺ and SSEA3⁻ cells ~~isolated from postpartum placenta perfusate~~, wherein at least one type of cell has been removed from the unit, and wherein at least ~~about one hundred~~ 1% of cells remaining in the unit are CD34⁺.

32. (Previously presented) The cyotherapeutic unit of claim 31 wherein a plurality of cell types has been removed from the unit.

33. (Canceled)

34. (Currently amended) A cyotherapeutic unit suitable for treatment of a patient in need of hematopoietic cells comprising a mixture of cells obtained from umbilical cord blood and isolated CD34⁻, OCT-4⁺ and SSEA3⁻ cells ~~isolated from postpartum placenta perfusate~~, said mixture of cells comprising a plurality of different types, at least one of the different types having been obtained from a source that differs from a source of another type and wherein at least ~~about one hundred~~ 1% of cells in said cyotherapeutic unit are CD34⁺.

35. (Previously presented) The cyotherapeutic unit of claim 34, wherein at least one of said types of cells has been frozen separately from another type of cells.

36. (Original) The cyotherapeutic unit of claim 34, in a frozen state.

37. (Previously presented) The cyotherapeutic unit of claim 34, wherein at least one of said cells has been characterized.

38.-53. (Canceled)

54. (Previously presented) The cyotherapeutic unit of claim 1, wherein said CD34⁻, OCT-4⁺ and SSEA3⁻ cells are additionally CD10⁺, CD29⁺, CD38⁻, CD44⁺, CD45⁻, CD54⁺, CD90⁺, SH2⁺, SH3⁺, SH4⁺, SSEA4⁻, and ABC-p⁺.

55. (Previously presented) The cyotherapeutic unit of claim 18, wherein said cells that are CD34⁻, OCT-4⁺ and SSEA3⁻ cells are additionally CD10⁺, CD29⁺, CD38⁻, CD44⁺, CD45⁻, CD54⁺, CD90⁺, SH2⁺, SH3⁺, SH4⁺, SSEA4⁻, and ABC-p⁺.

56. (Previously presented) The cyotherapeutic unit of claim 31, wherein said cells that are CD34⁻, OCT-4⁺ and SSEA3⁻ cells are additionally CD10⁺, CD29⁺, CD38⁻, CD44⁺, CD45⁻, CD54⁺, CD90⁺, SH2⁺, SH3⁺, SH4⁺, SSEA4⁻, and ABC-p⁺.

57. (Previously presented) The cyotherapeutic unit of claim 34, wherein said cells that are CD34⁻, OCT-4⁺ and SSEA3⁻ cells are additionally CD10⁺, CD29⁺, CD38⁻, CD44⁺, CD45⁻, CD54⁺, CD90⁺, SH2⁺, SH3⁺, SH4⁺, SSEA4⁻, and ABC-p⁺.